Abstract:Chronic infection of hepatitis B virus (HBV) remains a global public health problem and affects at least 240 million people worldwide. HBV is a small enveloped DNA virus belonging to the Hepadnaviridae family. The virus has a narrow host range, limited to humans and chimpanzees. In the nucleus of infected hepatocytes, the partially double-stranded DNA (rcDNA) HBV genome is converted to covalent closed circular DNA (cccDNA), which serves as the sole template for HBV transcription. HBV cccDNA exists as an episomal minichromosome in the nucleus, with a turnover rate that correlates with the mitosis or death of virus-infected hepatocytes. It is thus regarded as a primary molecular mechanism for viral persistence. In the past decade, significant progress has been made in HBV research and the related antiviral development. Sodium taurocholate co-transporting polypeptide (NTCP) has been identified as a receptor for HBV entry into hepatocytes. It was recently shown that HBV x (HBx), an enigmatic viral protein, achieves its regulatory function by hijacking the cellular DDB1-containing E3 ubiquitin ligase to target the Smc5/6 complex for degradation. Although still controversial, type I interferon has been implicated to either affect the epigenetic control of cccDNA minichromosome, or induce cytidine deaminases-mediated specific degradation of the episomal cccDNA. Of particular note, core protein allosteric modulator (CpAM) has been most widely investigated. These studies represent a new frontier in the development of antivirals against HBV infection. Despite continuing progress in HBV research, a complete cure of HBV infection is still not achievable. Current antiviral therapies with nucleos(t)ide analogs (NUC) and pegylated IFN-alpha can efficiently inhibit HBV replication, but the treatments fail to eliminate the preexisting cccDNA pool that is responsible for a viral rebound after therapy cessation. Therefore, it is widely held that cccDNA elimination is a prerequisite for complete cure of chronic HBV infection. To this end, it is essential to understand the mechanisms involved in cccDNA metabolism and transcriptional regulation. Studies of HBV cccDNA have often been hampered by the low copy number of cccDNA per cell and the lack of convenient techniques with high sensitivity and specificity for cccDNA detection. Development of appropriate experimental models is thus fundamental for HBV cccDNA studies. Herein, we reviewed recent advances in cell culture models for the study of HBV cccDNA, including models of HBV de novo infection and cccDNA biogenesis, cccDNA formation (rcDNA repair-related molecular events), HBV replicon-based transfection models to study established cccDNA, and the surrogate model of cccDNA produced from site-specific DNA recombination. Animal models to study HBV cccDNA will be further discussed by other authors in this issue. We hope this review may help clinicians and researchers who are interested in the study of cccDNA and antiviral development against HBV.

Hepatitis B: Model Systems and Therapeutic Approaches

Progress of Infection and Replication Systems of Hepatitis B Virus

Cytokines and Chemokines in HBV Infection

Animal Models for the Study of Hepatitis B Virus Pathobiology and Immunity: Past, Present, and Future

Animal Models for the Study of Hepatitis B Virus Infection.

HBV life cycle and novel drug targets

In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application

Establishment and application of in vitro and in vivo models of hepatitis B virus infection

New Insights into Hepatitis B Virus Biology and Implications for Novel Antiviral Strategies

Forthcoming Developments in Models to Study the Hepatitis B Virus Replication Cycle, Pathogenesis, and Pharmacological Advancements

Advances in HBV infection and replication systems in vitro

Development of Cell Culture Models for Hepatitis B Virus

In Vitro Cell Model and Mouse Model of HBV Cccdna

Overview of the Development of HBV Small Molecule Inhibitors

In Vitro Experimental Models for the Study of Hepatitis B Virus Cccdna

Recent Advances in Screening Methods Enabling the Discovery of Novel Anti-Hepatitis B Virus Drug Candidates

Current trends and advances in antiviral therapy for chronic hepatitis B

Establishment of Cell Culture Model and Humanized Mouse Model of Chronic Hepatitis B Virus Infection.

Research Progress of Mouse Model of Hepatitis B Virus Infection

Emerging Antivirals for the Treatment of Hepatitis B

Novel mechanistic insights – A brand new Era for anti-HBV drugs